Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Indacaterol 27.5 mcg, Indacaterol 37.5, Indacaterol 55 mcg, Indacaterol 75 mcg, Indacaterol 150 mcg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 12
States / cities: Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 9 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 54
States / cities: Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 56
States / cities: Huntsville, Alabama • *See Various Dept.'s*, Arizona • Tempe, Arizona + 46 more

Conditions: Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg, Placebo, Placebo/moxifloxacin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol/glycopyrrolate, indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Persistent Asthma
Interventions: Indacaterol, Placebo to Indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 21
States / cities: Anniston, Alabama • Cypress, California • Fresno, California + 16 more

Conditions: Hepatic Insufficiency
Interventions: QAB149; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: COPD
Interventions: Indacaterol, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 93
States / cities: Homewood, Alabama • Jasper, Alabama • Phoenix, Arizona + 83 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 69
States / cities: Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: Indacaterol/Glycopyrrolate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 80 Years
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Asthma
Interventions: Indacaterol maleate, Indacaterol acetate, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 47
States / cities: Vestavia Hills, Alabama • Huntington Beach, California • Lakewood, California + 43 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 53
States / cities: Anaheim, California • Escondido, California • Riverside, California + 45 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 58
States / cities: Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,042 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Birmingham, Alabama • Montgomery, Alabama • Mesa, Arizona + 60 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 74
States / cities: Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: NVA237, Long-acting beta 2-agonist (LABA), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 61
States / cities: Gulf Shores, Alabama • Mobile, Alabama • Tucson, Arizona + 52 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 118
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more

Conditions: Asthma
Interventions: Indacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 2,216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more

Conditions: Asthma
Interventions: Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 71
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more

Conditions: Asthma
Interventions: Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 56
States / cities: Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, NVA237, tiotropium, Salbutamol/albuterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 2,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 53
States / cities: Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 7
States / cities: Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more

Search by objective public record fields.

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Cardiac Safety of Indacaterol

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

Efficacy and Safety Study of QVA149 in COPD Patients

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma

Efficacy and Safety of Different Doses of Indacaterol

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)